Drug Trial Radar · NCT06103864
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
625
Planned (sponsor's estimate)
Start
Nov 23, 2023
Primary completion
Jul 28, 2027
Study completion Sep 30, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Oct 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Conditions
- Breast Cancer
Interventions
Dato-DXdDrug
Provided in 100mg vials. IV infusion. Experimental drug.
DurvalumabDrug
Provided in 500mg vials. IV infusion. Experimental drug.
PaclitaxelDrug
IV infusion. Active comparator.
Nab-paclitaxelDrug
IV infusion. Active comparator.
GemcitabineDrug
IV infusion. Active comparator.
CarboplatinDrug
IV infusion. Active comparator.
PembrolizumabDrug
IV infusion. Active comparator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).
Locations
318 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Daphne, Alabama · Recruiting
Research Site
Springdale, Arkansas · Recruiting
Research Site
Duarte, California · Withdrawn
Research Site
Fountain Valley, California · Recruiting
Research Site
Glendale, California · Recruiting
Research Site
Sacramento, California · Recruiting
Research Site
Santa Rosa, California · Withdrawn
Research Site
Aurora, Colorado · Recruiting
Research Site
Denver, Colorado · Not yet recruiting
Research Site
New Haven, Connecticut · Recruiting
Research Site
Altamonte Springs, Florida · Not yet recruiting
Research Site
Jacksonville, Florida · Withdrawn
Research Site
Miami, Florida · Recruiting
Research Site
Palm Bay, Florida · Withdrawn
Research Site
Plantation, Florida · Recruiting
Research Site
Atlanta, Georgia · Suspended
Research Site
Honolulu, Hawaii · Withdrawn
Research Site
Chicago, Illinois · Recruiting
Research Site
Decatur, Illinois · Withdrawn
Research Site
Elmhurst, Illinois · Withdrawn
Research Site
Naperville, Illinois · Withdrawn
Research Site
New Albany, Indiana · Withdrawn
Research Site
Des Moines, Iowa · Recruiting
Research Site
Lexington, Kentucky · Withdrawn
Research Site
Louisville, Kentucky · Withdrawn
Research Site
Louisville, Kentucky · Withdrawn
Research Site
Baton Rouge, Louisiana · Withdrawn
Research Site
Baton Rouge, Louisiana · Recruiting
Research Site
Baltimore, Maryland · Withdrawn
Research Site
Columbia, Maryland · Recruiting
Research Site
Boston, Massachusetts · Withdrawn
Research Site
Worcester, Massachusetts · Withdrawn
Research Site
Detroit, Michigan · Recruiting
Research Site
Grand Rapids, Michigan · Withdrawn
Research Site
Saint Paul, Minnesota · Recruiting
Research Site
Hattiesburg, Mississippi · Withdrawn
Research Site
St Louis, Missouri · Recruiting
Research Site
Albuquerque, New Mexico · Recruiting
Research Site
Albany, New York · Withdrawn
Research Site
New York, New York · Recruiting
Showing 40 of 318 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.